Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
- PMID: 38057067
- DOI: 10.1016/j.jacc.2023.10.020
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
Keywords: PCSK9; inclisiran; prevention; siRNA.
Conflict of interest statement
Funding Support and Author Disclosures Dr Ballantyne has received institutional grant/research support and consulting fees from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment on
-
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.J Am Coll Cardiol. 2023 Dec 12;82(24):2251-2261. doi: 10.1016/j.jacc.2023.10.007. J Am Coll Cardiol. 2023. PMID: 38057066
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
